$LLY (+1,78 %)
ZEPBOUND BEATS $NVO (-18,32 %) WEGOVY IN FIRST-EVER HEAD-TO-HEAD TRIAL - WSJ

In a Phase 3B study, Eli Lilly's Zepbound (tirzepatide) outperformed Novo Nordisk's Wegovy (semaglutide) in weight loss outcomes. Over 72 weeks, participants on Zepbound achieved an average 20.2% body weight reduction (50.3 lbs), compared to 13.7% (33.1 lbs) for Wegovy.

This marks the first direct comparison between the two obesity drugs, highlighting Zepbound's 47% greater relative weight loss advantage. The trial included over 750 adults with obesity or weight-related complications, excluding those with diabetes.